Portraying breast cancers with long noncoding RNAs by Van Grembergen, Olivier et al.
R E S EARCH ART I C L EEP IGENET IC S1Laboratory of Cancer Epigenetics, Faculty ofMedicine, ULB–Cancer ResearchCenter (U-CRC),
Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium. 2Machine Learning Group, Com-
puter Science Department, Université Libre de Bruxelles, 1050 Brussels, Belgium. 3Inter-
university Institute of Bioinformatics Brussels, Université Libre de Bruxelles–Vrije Universiteit
Brussel, 1050 Brussels, Belgium. 4Breast Cancer Translational Research Laboratory, Jules Bordet
Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium. 5Department of Gastroenterol-
ogy andHepatology, Chinese People’s Liberation ArmyGeneral Hospital, Beijing 100853, China.
*Corresponding author. Email: ffuks@ulb.ac.be
Van Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 20162016 © The Authors, some rights reserved;
exclusive licensee American Association for
the Advancement of Science. Distributed
under a Creative Commons Attribution
NonCommercial License 4.0 (CC BY-NC).
10.1126/sciadv.1600220Portraying breast cancers with
long noncoding RNAs
Olivier Van Grembergen,1 Martin Bizet,1,2,3 Eric J. de Bony,1 Emilie Calonne,1 Pascale Putmans,1 Sylvain Brohée,4
Catharina Olsen,2 Mingzhou Guo,5 Gianluca Bontempi,2,3 Christos Sotiriou,4 Matthieu Defrance,1,3 François Fuks1*Evidence is emerging that long noncoding RNAs (lncRNAs) may play a role in cancer development, but this role is not
yet clear. We performed a genome-wide transcriptional survey to explore the lncRNA landscape across 995 breast
tissue samples. We identified 215 lncRNAs whose genes are aberrantly expressed in breast tumors, as compared to
normal samples. Unsupervised hierarchical clustering of breast tumors on the basis of their lncRNAs revealed four
breast cancer subgroups that correlate tightly with PAM50-definedmRNA-based subtypes. Usingmultivariate analysis,
we identified no less than 210 lncRNAs prognostic of clinical outcome. By analyzing the coexpression of lncRNA genes
and protein-coding genes, we inferred potential functions of the 215 dysregulated lncRNAs. We then associated
subtype-specific lncRNAs with key molecular processes involved in cancer. A correlation was observed, on the one
hand, between luminal A–specific lncRNAs and the activation of phosphatidylinositol 3-kinase, fibroblast growth
factor, and transforming growth factor–b pathways and, on the other hand, between basal-like–specific lncRNAs and
the activation of epidermal growth factor receptor (EGFR)–dependent pathways and of the epithelial-to-mesenchymal
transition. Finally, we showed that a specific lncRNA,whichwe called CYTOR, plays a role in breast cancer.We confirmed
its predicted functions, showing that it regulates genes involved in the EGFR/mammalian target of rapamycin pathway
and is required for cell proliferation, cell migration, and cytoskeleton organization. Overall, our work provides the most
comprehensive analyses for lncRNA in breast cancers. Our findings suggest a wide range of biological functions as-
sociated with lncRNAs in breast cancer and provide a foundation for functional investigations that could lead to new
therapeutic approaches.INTRODUCTION
Breast cancer is amajor public health issue. According to themost recent
worldwide cancer statistics, more than 1,675,000 women are diagnosed
with this disease each year andmore than 500,000 die of it (1). Breast
cancer is a heterogeneous disease, and different subtypes have been de-
scribed (2). Beyond the classic grading system (based on tumor cell dif-
ferentiation status) and the TNM (tumor size, lymph node involvement,
andmetastasis) classification, breast tumors are also classified on the
basis of protein and gene status. Clinically, breast tumors are subclassified
into three main subgroups on the basis of estrogen receptor (ER) and
human epidermal growth factor receptor 2 (HER2) gene expression: ER-
positive tumors (themost frequently diagnosed subtype), HER2-positive
tumors (harboring an ERBB2 amplification), and triple-negative breast
cancers lacking ER, HER2, and the progesterone receptor (3). Addi-
tionally,microarray-based codingmRNAexpression profiling has iden-
tified five “intrinsic” subtypes (2). Luminal A (low-grade) and luminal B
(high-grade) tumors are predominantly ER+. TheHER2+ subtypemostly
comprises tumors overexpressing theHER2+gene.Thebasal-like subtype
is particularly frequent among triple-negative cancers. The least frequent
subtype, called “normal-like,” comprises tumors that have an expression
pattern similar to that of normal breast tissues. Recently, because of
whole-transcriptome sequencing [RNA sequencing (RNA-seq)], this
classification has been refined, with the identification of 12 breast tumor
subgroups (4). Despite these advances, we are far from completelyunderstanding breast cancer heterogeneity because tumors of the
same subtype can respond differently to therapy and can have different
outcomes (5, 6). Understanding the molecular mechanisms that
underlie breast cancer heterogeneity thus remains a major challenge
improving diagnosis and therapy, and new approaches are needed to
meet this challenge. Recent work has suggested that long noncoding
RNAs (lncRNAs) and small noncoding RNAs (such as microRNAs)
might play key roles inmammary tumor development (7, 8) and provide
new biomarkers and potential targets for future therapies.
lncRNAs are transcripts more than 200 base pairs long that lack
an extended open reading frame and thus do not code for proteins (9).
According to recent studies, the human transcriptome contains up to
16,000 lncRNAs, frequently spliced and polyadenylated, whose genes
are mainly transcribed by RNA polymerase II (9). Expression of lncRNA
genes is lower than that of protein-coding genes, but is tissue-specific (9).
In recent years, studies have linked lncRNAs to a wide variety of phys-
iological and pathological mechanisms, including pluripotency regulation
and cancer development (10). Like proteins, lncRNAs may mediate on-
cogenic or tumor-suppressive effects (10, 11). They can exert various
functions in the cytoplasm (for example, as scaffolds between proteins
or as microRNA sponges) and the nucleus (10). They have emerged as
key players in the transcriptional regulation of protein-coding genes, in
which case they can act either distally (in trans) or proximally (in cis)
(10). For instance, the lncRNA HOTAIR (HOX transcript antisense
RNA), which is up-regulated in some breast cancer tissues and whose
expression is associated with poor prognosis and tumor metastasis, is
suggested to silence tumor suppressor genes (7, 10). Other lncRNAs
appear as key regulators of pathways underlying carcinogenesis; an
example is lincRNA-p21, which mediates global gene repression in the
p53 response (12). Genome-wide association studies on cancer have1 of 15
R E S EARCH ART I C L Erevealed that more than 80% of cancer-associated single-nucleotide
polymorphisms occur in noncoding regions. This suggests that a sig-
nificant fraction of the genetic etiology of cancer is related to lncRNAs
(13). Previous studies have documented aberrantly expressed lncRNA
genes in breast tumors and have notably established associations
between certain lncRNAs and known gene expression–based breast
cancer subtypes (14, 15). However, these lncRNAs have not been pre-
cisely related to molecular pathways, and their functions have not
been investigated.
The goal of the present study was to explore lncRNA landscape in
breast cancers and to extract novel biological and clinical information.
On the basis of an array-based transcriptional survey ofmore than 3000
lncRNA genes, we have identified lncRNAs aberrantly expressed across
823 breast tumors, as compared to 172 normal samples. Although gene
chips contain less lncRNAs than other technologies for which data are
publicly available (for example, RNA-seq), we used microarray data for
the following reasons: (i) low technical variation (16–18), (ii) strand
specificity, (iii) larger number of publicly available data, and (iv) long
follow-up clinical annotation.
From our in-depth analyses, we have inferred potential functions of
dysregulated lncRNAs and demonstrated their relevance to breast
cancer classification.We have investigated lncRNAs as survivalmarkers,
associating several of themwithprognosis. Finally,wehave experimentally
characterized the functions of one breast cancer–related lncRNA—CYTOR
(cytoskeleton regulator). Overall, this work provides the most compre-
hensive data sets so far for lncRNA in breast cancers. It highlights the
influence of lncRNAs in numerous pathways that are dysregulated in tu-
mors andmayprovidenovel approaches to cancerprognosis and treatment.RESULTS
Breast tumors display lncRNA gene expression profiles that
are distinct from those of normal breast tissues
Seven data sets from the Gene Expression Omnibus (GEO) data re-
pository (19) were selected and compiled to generate a large cohort of
823 breast tumors and 172 normal breast tissues (Fig. 1A and table S1).
The data sets were selected on the basis of their size (more than 50
samples), the presence of breast tumors from each subtype, and ex-
tensive clinical annotation, including relapse information. To increase
the number of normal samples, we included the GSE10780 series that
profiled 143 normal breasts and 42 tumors.
First, we reannotated the entire collection of probe sets of the Affy-
metrix HumanGenomeU133 Plus 2.0 Array to analyze levels of 16,951
mRNAs and 3053 lncRNAs (table S2). When the distribution of
lncRNAgene expression levels across all breast tissue samples was com-
pared with that of coding gene expression levels, it was confirmed that
the former generally show lower level expression than do the latter (fig.
S1A) (9). On the basis of the observed lncRNA gene expression profiles
in tumors and normal breast tissues, we then performed unsupervised
consensus clustering (20, 21) and identified three robust clusters, one of
which (cluster II) contained almost all of the normal samples (95%) (P
value of the association = 2.3 × 10−164). Cancer and healthy tissues thus
appear to have different lncRNA gene expression profiles (Fig. 1B). We
therefore sought to identify lncRNAs whose genes are differentially
expressed in breast tumors versus normal breast tissue. Because of the
heterogeneity of breast cancer, we did not apply the classical t test but
adapted a method that allows detection of differentially expressedVan Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016lncRNAs in a fraction of cancer samples (22).We identified 215 lncRNAs
whose genes appeared aberrantly expressed in at least 10% of the breast
tumors (see Materials and Methods, fig. S1B, and table S3). Among
these 215 lncRNAs, 124 appeared up-regulated and 91 appeared down-
regulated in breast cancer (Fig. 1, C and D, top). Some of these iden-
tified lncRNAs have already been described as involved in breast cancer
development, such as HOTAIR, MALAT1, H19, and GAS5 (10, 14).
The genes that encode the 215 identified lncRNAs appeared scattered
across the genome, without any focal hot spot (fig. S1C).
We next examined whether lncRNA levels, like the levels of protein-
coding transcripts, can serve as biomarkers for breast cancer diagnosis.
For this, we generated an lncRNA metagene and assessed its ability to
discriminate tumor samples from healthy ones. In the discovery data
set, significant discrimination of breast tumors from healthy samples
was achieved (P<0.0001)with high specificity (0.96) andhigh sensitivity
(0.95). To validate our findings on an independent data set, we used
RNA-seq data from The Cancer Genome Atlas (TCGA) consortium
reanalyzed by Rahman et al. (23) that we called “validation set 1A.”
This processed data set allows assessment of the expression of 1161
lncRNAs from 1052 breast tumors and 113 normal samples. On the
basis of lncRNA expression, we performed unsupervised hierarchical
clustering and observed three stable clusters (Fig. 1E), one of which
contained almost all of the normal samples, suggesting that our re-
sults could be extended to independent cohorts profiled by RNA-seq.
Of the 215 lncRNAs identified as dysregulated in the discovery cohort,
we could assess the expression of 87 lncRNAs present in the RNA-seq
data set. Of them, 82 were dysregulated in the RNA-seq data (see ex-
amples in Fig. 1D, bottom). In addition, the expression pattern of a
metagene that represents the expression of these 87 lncRNAs allowed
highly accurate classification of the cancer versus normal samples
(specificity, 0.98; sensitivity, 0.93; P < 0.0001) (fig. S1D). We also re-
annotated the custom Agilent 244K microarray used by the TCGA
consortium (4). Of the 215 dysregulated lncRNAs identified from the
discovery cohort, 167 were detectable on the TCGAmicroarray, which
we called “validation set 1B.” The expression patterns of the cor-
responding genes allowed a highly predictive classification of breast
cancer and normal breast tissues in the TCGA validation set com-
posed of 524 breast tumors and 63 normal tissues (specificity, 0.97;
sensitivity, 0.98; P < 0.0001) (fig. S1E). Together, these analyses provide
a validated set of lncRNAs that are dysregulated in breast tumors, as
compared to normal human samples.
lncRNA expression is associated with ER signaling
On the basis of hierarchical clustering (Fig. 1B), we noticed that breast
tumors are separated into two different clusters, and we further
searched for their relationship with clinical properties. We observed
a significant association with the immunohistochemistry (IHC)–based
ER status, that is, marked differential expression of lncRNAs between
ER-positive and ER-negative tumors. Cluster I was found to contain
91% ER-positive tumors (P value of the association = 6.7 × 10−61),
whereas cluster III contained 76% ER-negative tumors (P value of
the association = 3.6 × 10−63) (Fig. 2A and table S4). Given this
finding, we next used a supervised approach to identify lncRNAs speci-
fically associated with the ER status. From the whole set of lncRNAs
(that is, 3053 lncRNAs), our analysis revealed 38 lncRNA genes dif-
ferentially expressed betweenER-positive andER-negative breast tumors,
determined by IHC [false discovery rate (FDR) < 0.05; fold change
> 1.5, t test] (see examples in Fig. 2B). Whereas an association between2 of 15
R E S EARCH ART I C L EFig. 1. lncRNA gene expression profiling in breast tissues reveals 215 dysregulated lncRNAs. (A) Description of the human breast tissues analyzed in
this study. (B) Unsupervised consensus clustering of the samples on the basis of lncRNA gene expression. Primary tumors (823) and normal samples (172)
were used for hierarchical clustering on the basis of the 500 most variant lncRNAs (based on SD). (C) Pie chart showing, among the lncRNAs that are dysre-
gulated in breast tumors versus normal tissues, the numbers of down- and up-regulated ones. (D) Box plot for expression levels of the top dysregulated
lncRNAs in the discovery cohort (top) and their expression in the TCGA RNA-seq cohort (bottom). Notches are used to compare groups; if the notches of two
boxes do not overlap, themedians differ significantly. The whiskers extend to themost extreme data point, which is nomore than 1.5 times the interquartile
range of the box. (E) Same as in (B) for the TCGA RNA-seq cohort composed of 1052 breast tumors and 113 normal samples.Van Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016 3 of 15
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(24),MALAT1 (25), andXist (26)] had previously been evidenced,most
lncRNAs highlighted here are novel in the context of breast cancer. This
is the case for LINC01297, the most significantly up-regulated lncRNA
in ER-positive tumors, and RP11-303E16.2, themost significantly down-
regulated lncRNA in these tumors (Fig. 2B). Notably, 32 of the 38 ER-
associated lncRNAswere alsodysregulated inbreast tumors, as compared
to normal samples.
We next used different data sets [validation set 1A (RNA-seq data
fromTCGA), validation set 1B (microarray data fromTCGA), and val-
idation set 2 (GSE20685)] to assess to what extent one could predict the
ER status on the basis of expression levels of the lncRNA genes identi-
fied above. In validation set 1A (TCGA RNA-seq), we assessed the ex-
pression of 12 of the 38 lncRNAs from the ER-associated lncRNAs and
found that their expression allowed highly accurate prediction of the ER
status (specificity, 0.93; sensitivity, 0.83; P < 0.0001). Validation set 1B
(TCGAmicroarray) was generated on a different microarray platform,
which allowed assessment of the expression of 29 of the 38 lncRNAVan Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016genes identified. The expression patterns of these 29 lncRNA were
again highly predictive of the ER status (specificity, 0.89; sensitivity,
0.78;P< 0.0001). Finally, in theGSE20685 data set, the expression of the
38 genes can also predict the ER status, with a specificity of 0.86 and a
sensitivity of 0.91 (P < 0.0001). Prediction of the ER status on the basis
of these patterns was thus highly reproducible (fig. S2).
To gain insight into the biological relevance of the 38 lncRNAs,
we used the “guilt-by-association” approach (27) to investigate their
relationship to different pathways (see Materials andMethods). Briefly,
we computed the matrix of correlation between lncRNA levels and
expression levels of protein-coding genes across all breast cancer samples
and then generated hypotheses regarding the function(s) of each dys-
regulated lncRNA on the basis of the known biological functions and
themolecular pathways of protein-coding genes that show a good cor-
relation (table S5). We used hierarchical clustering to subdivide the 38
lncRNAs that constitute the ER signature into three groups on the
basis of their levels in the various tumors (Fig. 2C). This analysis re-
vealed enrichment in key breast cancer–related pathways for each groupFig. 2. lncRNA gene expression profiling identifies two main breast tumor categories differing with regard to ER status. (A) Dendrogram of 823
primary tumors and 172 normal samples obtained by consensus hierarchical clustering of the samples on the basis of expression of the top 500most variant
lncRNAs. Clusters I and III, encompassing almost all tumors, are related to the ER status. (B) Box plot illustrating the expression levels of five lncRNA genes
differentially expressed between ER+ and ER− tissues. Notches are used to compare groups; if the notches of two boxes do not overlap, the medians differ
significantly. Thewhiskers extend to themost extremedata point, which is nomore than 1.5 times the interquartile range of the box. (C) Heatmap illustrating
the expression of the 38 lncRNA genes (rows) of the ER signature across the breast tumors (columns). The lncRNAs in bold represent lncRNAs dysregulated
between breast cancer and normal samples. The color scale of the heat map indicates the relative expression of each lncRNA gene. Hierarchical clustering
reveals three clusters of lncRNAs. For each cluster, the most significant functional enrichment term from the guilt-by-association analysis is shown.4 of 15
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in ER-positive tumors, appeared to correlatemost strongly withmam-
malian target of rapamycin (mTOR) pathway inhibition. Group 2
lncRNAs appeared most strongly related to E2F1 pathway activation.
Group 3 contained lncRNAs that are potentially involved in inhibition
of immunity. Overall, our findings suggest that lncRNA levels can dis-
tinguish ER+ from ER− tumors and that lncRNAs are involved in var-
ious processes beyond ER biology. This sheds new light on pathways
related to the ER status of breast cancers, such as the mTOR pathway
and immunity (4, 28, 29).
Identification and inferred functions of lncRNAs that are
associated with molecular subtypes of breast cancers
We next examined the relationship between the expression of lncRNA
genes and the intrinsic breast tumor subtypes. lncRNA level–based con-
sensus clustering of the 823 tumors identified four robust clusters (as-
sessed by the ConsensusClusterPlus algorithm). There was also good
agreement between lncRNA-based clusters and PAM50-definedmRNA-
based subtypes: clusters 1, 2, 3, and 4 were found to contain 96% basal-
like (P value of the association= 1.9×10−142), 52%HER2+ (P value of the
association = 2.6 × 10−60), 84% luminal A (P value of the association =
1.6 × 10−50), and 64% luminal B (P value of the association = 1.8 × 10−47)
samples, respectively (P = 1.2 × 10−242, c2 test) (table S6). We thus usedVan Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016the PAM50 classification as a reference to identify molecular subtype–
specific lncRNAs, which defines a specific lncRNA signature for each
breast cancer subtype (see Materials and Methods). These signatures
consisted of 42 lncRNAs (36 up-regulated and 6 down-regulated) for
luminal A, 9 (8 up-regulated and 1 down-regulated) for luminal B, 14 (8
up-regulated and 6 down-regulated) forHER2+, and 74 (28 up-regulated
and 46 down-regulated) for the basal-like subtype (Fig. 3B and table S7).
The large size of the basal-like signature distinguishes the basal-like sub-
type as particularly perturbed at the level of lncRNA gene expression.
Again, we looked at the predictive values of these signatures in the
validation data sets used previously [validation set 1A (RNA-seq data
fromTCGA), validation set 1B (microarray data fromTCGA), and val-
idation set 2 (GSE20685)].We found each subtype-specific lncRNA sig-
nature to identify with high-efficiency samples belonging to the
considered subtype. As in the case of subtype mRNA signatures (30),
the best prediction scores were obtained for the basal-like subtype, thus
confirming that this subtype has a more distinct profile than the others.
Overall, these analyses performed on cohorts independent of our initial
823 tumor samples validated the four subtype-specific signatures (fig. S3).
We next wondered whether these subtype-specific lncRNAs might
be globally related to the alteration of different biological functions and
molecular pathways. To investigate this, we again used the guilt-by-
association approach, relating the functions predicted for subtype-specificFig. 3. Identification of four lncRNA-related clusters correlating with the known molecular subtypes and enriched in specific functional terms.
(A) Dendrogram of the 823 breast tumors obtained by consensus hierarchical clustering according to the levels of the 500 most variant dysregulated
lncRNAs, revealing four groups of tumors (clusters I to IV). How these clusters relate to the mRNA-based breast cancer subtype (based on PAM50) is also
shown. (B) Histogram illustrating the number of specific lncRNAs in each molecular subtype of breast cancer. (C) Heat map illustrating the pathways whose
activation or inhibition correlates with levels of subtype-specific lncRNAs andmRNAs. To relate subtype-specific lncRNAs to gene sets, an enrichment meta-
score was computed for each gene set. The P value of themetascore was defined as the proportion of randommetascores being at least as high (low) as the
metascore of the positively (negatively) subtype-specific lncRNAs. Conventional GSEA analysis was used to analyze specific enrichment inmRNAs, comparing
one subtype to the three others. The significance scorewas defined as the log of the P value, adjusted by the sign of the enrichmentmetascore. (D toG) Heat
maps illustrating the enrichment scores of subtype-specific lncRNAs for representative gene sets in the (D) luminal A, (E) luminal B, (F) HER2+, and (G) basal-like
subtypes. A positive (negative) score is associated with the activation (repression) of the gene set.5 of 15
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observed good agreement between the two sets of predicted functions. In
the basal-like subtype, for example, we found both predicted lncRNAs
and mRNAs to be associated with cell cycle activation and the RAF
[mitogen-activated protein kinase (MAPK)] and MYC pathways; yet,
therewere caseswhere subtype-specific lncRNAs appearedmore strongly
associatedwith a functionorpathway than subtype-specificmRNAs.This
was true for angiogenesis stimulation and activation of phosphatidylino-
sitol 3-kinase (PI3K), fibroblast growth factor (FGF), and transforming
growth factor–b (TGF-b) pathways in the luminal A subtype and for ac-
tivation of epidermal growth factor receptor (EGFR) and lymphoid
enhancer binding factor 1 (LEF1) pathways in the basal-like subtype.
We then took a closer look at predicted functions of subtype-specific
lncRNAs. Within each subtype-specific lncRNA signature, we first
performed hierarchical clustering of the lncRNAs on the basis of their
coexpression with coding mRNAs and then examined which biological
functions or molecular pathways appeared overrepresented in each
group (Fig. 3, D to G).We observed three functional groups for luminal
A–specific lncRNAs: lncRNAs related to the PI3K pathway, lncRNAs
associated with the epithelial-to-mesenchymal transition (EMT), and
lncRNAs related to immunity (Fig. 3D). Hierarchical clustering of the
nine lncRNAs that compose the luminal B signature identified one
main lncRNA group related to the MAPK pathway, including a group
of lncRNAs enriched for the RAF pathway and one additional lncRNA
associated with the activation of theMYCpathway (Fig. 3E).We iden-
tified two functional groups of HER2+-specific lncRNAs: one related to
the mTOR pathway and one related to the PI3K pathway. This sec-
ond functional cluster encompasses lncRNAs related to the p53 path-
way, known to be influenced by the PI3K pathway in the context of
HER2+ tumors (Fig. 3F) (31). Three groups of basal-like–specific
lncRNAs were identified: group 1, which contains lncRNAs whose
genes are coexpressed with E2F1 target genes; group 2, which is related
to interleukin-6 (IL-6) production andpartly to the EGFRpathway [two
pathways known to be interconnected (32)]; and group 3, which ismore
specifically related to the EGFR pathway (Fig. 3G).
Together, our analyses highlight important putative functions for
subgroups of subtype-specific lncRNA genes whose expression correlates
tightly with that of cancer-related coding genes. Moreover, some groups
of subtype-specific lncRNAs are involved in common pathways (that
is, the PI3K pathway), whereas others appear more specialized (that is,
group 3 in the basal-like subtype, which is related to E2F1). Our results
show that some lncRNAs seem to be more significantly regulated in
many pathways than mRNAs. This illustrates the importance of
lncRNAs in breast cancer.
Dysregulated lncRNAs are markers of breast cancer
clinical outcome
Like protein-codingRNAs, several lncRNAshave been linked to clinical
outcome indifferent diseases (33).We thus used univariateCox regression
models to assess whether expression levels of lncRNAsmight correlate
with relapse-free survival, using our discovery data set with long follow-
up (median follow-up, 6.75 years). No less than 300 lncRNAs emerged
as significantly prognostic markers of risk of relapse (table S8), in-
cluding 41 lncRNAs dysregulated in breast cancer, as compared to
healthy tissues. Next, we performedmultivariate Cox analysis to examine
the possible impact of confounding factors known to affect prognosis
(size, node, grade, ER, and HER2). The expression of 210 lncRNAs
appeared to be significant risk-of-relapse predictors in this analysis, sug-Van Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016gesting that these lncRNAs could be independent prognostic factors
(Fig. 4A and table S9).Most of them are novel survivalmarkers in breast
cancer, including the newly identified RP11-863K10.2, which has the
highest hazard ratio (HR) in our study (HR, 8.5; P= 0.007) (Fig. 4, B and
C), andLINC00152,whichwe calledCYTOR[following theHUGOGene
Nomenclature Committee guidelines (34)] (HR, 1.42; P= 0.012) (Fig. 4,
D and E), an lncRNA up-regulated in all subtypes of breast cancer and
recently revealed as a marker of gastric cancer (35). As shown in Fig. 4,
Kaplan-Meier curves highlighted significant differences in relapse-free
survival between patients whose tumors showed high and low levels of
certain lncRNAs.
Twenty-seven of the 210prognostic lncRNAswere also dysregulated
in breast cancer, as compared to normal tissues, suggesting their impor-
tance in terms of biological relevance. We sought to validate this set of
27 dysregulated and prognostic lncRNAs using a metagene-based ap-
proach. As shown in fig. S4, we observed similar Cox HR values for the
prognostic lncRNAs in the discovery cohort (HR, 1.23; P = 1.9 × 10−6)
and in an independent validation cohort composed of 327 samples with
a median follow-up of 9.2 years (HR, 1.22; P = 2.2 × 10−5; validation P
value = 0.0029). Together, the above results suggest that a set of 27 dys-
regulated lncRNAs might be used as novel independent markers re-
liably predicting the risk of relapse in breast cancer.
CYTOR is required for cell proliferation, cell migration, and
cytoskeletal organization
We selected CYTOR (previously known as LINC00152) for further
functional characterization and experimental validation of the guilt-
by-association prediction. CYTOR is an intergenic lncRNA located
more than 100 kb away from the nearest protein coding (PLGLB2) in
the chromosome2p11.2.Wechose this lncRNAfor the following reasons:
(i) CYTORmay be a general tumor marker because it is up-regulated in
all subtypes of breast cancer (Fig. 5A) and in other types of cancer such as
thyroid, stomach, lung, renal, and liver cancer (36); (ii) CYTOR is prog-
nostic of relapse in both our discovery and validation cohorts; (iii) our
guilt-by-association analysis highlighted an association between lncRNA
and key cancer-related pathways such as cell proliferation, cell migration,
and EMT and the EGFR, mTOR, and MAPK pathways (Table 1).
In addition to this, the transcription start site of CYTOR appears
associated with H3K27 acetylation, H3K4 trimethylation, and weak
H3K4 monomethylation marks in different breast cancer cell lines
[MDA-MB-231 (Fig. 5B), HMEC, and MCF-7 (fig. S5A)], suggesting
that this intergenic lncRNA is transcribed from promoter-like elements
(37). The promoter DNAmethylation profile of CYTOR in tumors and
various breast cell lines suggests that it may be regulated byDNAmeth-
ylation in breast tumors (fig. S5, B and C).
To assess the function of CYTOR, we used locked nucleic acid
(LNA) gapmers to efficiently knock down CYTOR in MDA-MB-231
breast cancer cells (fig. S6A), wherein the basal level of CYTOR is high.
Silencing of CYTOR resulted in a significant decrease in cell proliferation,
as assessed with xCELLigence technology (Fig. 5C). In 5-bromo-2′-
deoxyuridine (BrdU)/7-aminoactinomycin D (7-AAD) flow cytometry
experiments, CYTORknockdown cells accumulated in theG2/Mphase,
at the expense of the S phase, confirming cell cycle inhibition (fig. S6,
B and C). Thus, CYTOR is required for normal proliferation and cell
cycle progression. We then evaluated the effect of CYTOR knockdown
on cell migration, another process predicted to be affected by the guilt-
by-association analysis. Cell migration kinetics was recorded with the
xCELLigence system,using fetal bovine serum(FBS) as a chemoattractant.6 of 15
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With FBS, control cells migrated, whereas cells depleted for CYTOR
did not (Fig. 5D).
We next examined the possible role of CYTOR in controlling gene
expression. In genemicroarray experiments on control and CYTOR-
knockdownMDA-MB-231 cells, we found 2 genes that are up-regulated
and 79 genes that are down-regulated in the latter (fold change > 1.5;
FDR < 0.05) (Fig. 5E), suggesting a rather positive role for this lncRNA
in gene regulation. Some of the identified targets are involved in breastVan Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016cancer [KIF14 (38) andGOLPH3 (39)], some are involved in key sig-
naling pathways (for example, mTOR, PRKCA, and IGFR2), and
some are involved in cytoskeleton remodeling [for example, tubulin
tyrosine ligase (TTL), Rho guanosine triphosphatase (GTPase) (Rhobtb3),
and plakophilin-4 (PKP4) (40)]. Note that none of the genes in the large
neighborhood (±1Mb) ofCYTORwas affected by the knockdown, sug-
gesting that this lncRNA acts in trans. We selected five CYTOR target
genes (mTOR, GOLPH3, KIF14, PRKCA, and SMYD3) for validation by
reverse transcription quantitative polymerase chain reaction (RT-qPCR)Fig. 4. lncRNAs in breast cancer have prognostic value. (A) Forest plot showing the log2 HR with the SD (blue boxes) and the 95% confidence interval
(bars) of the relapse-free survival analysis (multivariate Cox analysis). A negative HR reveals that a high lncRNA level is associated with a good outcome, and
conversely. For example, five lncRNAs significantly related to relapse are shown. *P < 0.05, **P < 0.01. (B) Multivariate analysis with all the classical markers
used clinically. RP11-863K10.2 is used as an example (see table S9 for the complete analysis). CI, confidence interval. (C) Exemplative Kaplan-Meier curves for
RP11-863K10.2 (P = 0.01, log-rank test). (D) Same as in (B) for CYTOR. (E) Same as in (C) for CYTOR (P = 0.000776, log-rank test).7 of 15
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transcript-level expression (fig. S6D). Furthermore, Ingenuity Pathway
Analysis of the targets revealed significant overrepresentationof pathways
related to EGFR andMAPK signaling (Fig. 5F and fig. S6E), as predicted
by our guilt-by-association analysis (Table 1). The most overrepresented
term was cell spreading, a process driven by actin polymerization and
promoted by the Rho family of GTPase and the mTORC2 complex
(41, 42). Therefore, we stained the filamentous actin (F-actin) cyto-
skeletonwithActi-stain 488 fluorescent phalloidin in cells treated with
the LNA gapmer targeting CYTOR, or with LNA control cells. The
former cells appeared smaller and rounder than the latter, and global re-
organization of actin fibers was observed in these cells, with fewer stress
fibers and thick actin fibers present mainly on the cell cortex (Fig. 5G).
Overall, these results indicate that CYTOR, which correlates with
poor outcome, is required for breast cancer cell growth, migration,
and normalmorphology. They also show that CYTORmay act in trans
to control genes involved in the mTOR pathway. It may thus be a good
candidate target for new therapeutic approaches.DISCUSSION
Although previous studies have demonstrated the involvement of
lncRNAs in breast cancer pathology (14, 15), the functions they exertVan Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016in breast cancer development remain poorly understood. Themicroarray
approach we used here is limited to detecting lncRNAs that are known
and present on the Affymetrix U133 Plus design. However, while repre-
senting a fraction of lncRNAs encoded by the human genome, our inte-
grative analysis also brings significant insights and advances over previous
studies because it provides the most comprehensive data sets so far for
breast cancers, a resource of clinically relevant lncRNAs, and a potential
lncRNA function in the breast cancer context and uncovers their utility
in prognosis. It is worth adding that the clinical information available
from the array-based expression profiles aremore extensive than publicly
available data from the TCGARNA-seq experiment, especially in terms
of median follow-up [median follow-up of 6.75 years for the discovery
cohort and 9.2 years for the validation cohort, in comparison to 1.08 years
for the biggest RNA-seq cohort publicly available from the TCGA
consortium (4)]. Our work provides an important foundation for the
potential function and clinical relevance of lncRNA in breast cancers,
and future work would certainly be valuable to extend our results to the
entire set of lncRNAs, notably by RNA-seq.
Here, we show that 215 lncRNAs are dysregulated in breast cancers.
Using (i) already processed TCGA RNA-seq data, hence easily usable,
and (ii) two independentmicroarray cohorts, we could validate our dis-
covery signature on data profiled by two different technologies.We also
demonstrated an associationbetween lncRNAs and clinical features and
relapse. In terms of function, these lncRNAs appear to be associatedwithFig. 5. CYTOR controls cell proliferation, cell migration, and cytoskeleton organization. (A) Expression of the gene encoding CYTOR in the discovery
data set (823 tumors and 172 normal breast samples) and the TCGA RNA-seq data set GSE62944 (971 tumors and 103 normal breast samples). (B) UCSC
(University of California, Santa Cruz) genome browser view of chromosome locus 2p11.2, which contains CYTOR. Themagnified view depicts CYTOR with its
associated histone marks (H3K27 acetylation, H3K4 trimethylation, and H3K4 monomethylation, from GSE49651) and methylation marks in MDA-MB-231
cells. The unfilled lollipop represents unmethylated CG dinucleotides from the Infinium HumanMethylation450. (C) Proliferation curve of MDA-MB-231 cells
with and without LNA gapmer–mediated knockdown of CYTOR. A real-time cell analyzer (RTCA) software representative trace of a triplicate experiment is
shown. (D)Migration kinetics ofMDA-MB-231 cells assessed by continuousmonitoring for approximately 24 hours. FBS (10%) in the lower chamberwas used
as chemoattractant, except for the control curve (purple), which represents untransfected cells with serum-free medium in the lower chamber. An RTCA
software representative trace of a triplicate experiment is shown. (E) Pie chart and heat map showing the distribution of differentially expressed genes after
CYTOR knockdown in MDA-MB-231 cells. (F) Enriched pathways (left) from Ingenuity Pathway Analysis in CYTOR knockdown cells. Representative differen-
tially expressed genes of enriched gene sets are shown on the right (see also fig. S6E.) (G) Staining of F-actin with Acti-stain 488 fluorescent phalloidin (green)
and of DNAwith 4′,6-diamidino-2-phenylindole (blue) reveals reorganization of the actin cytoskeleton inMDA-MB-231 cells transfected with an LNA gapmer
against CYTOR (right), as compared to cells transfected with a control LNA gapmer (left). Images captured with a 40× objective are shown.8 of 15
R E S EARCH ART I C L Enumerous key molecular processes, including the EGFR, PI3K, MAPK,
andE2F1 pathways. In addition, we find thatCYTOR, an lncRNA that is
dysregulated in breast cancer and is associated with bad outcome, is
essential to theproliferation,migration, andnormalmorphologyof breast
cancer cells.
Our in-depth transcriptomic analysis has revealed that lncRNApro-
filing of breast tumors distinguishes ER+ from ER− tumors and allows
stratification into differentmolecular subtypes, in agreementwith findings
of recent studies (14,15). ByRNA-seq inbreast cancer cell lines, two recent
studies identified lncRNAs regulated by the ER in the presence or absence
of an estrogen agonist (43, 44). However, we found only two lncRNAs
(DSCAM-AS1 and RP11-161M6.2) that overlap with our ER-related
signature and also between these two studies themselves, suggesting dif-
ferential mechanism between cell lines and tissues and/or specificities
related to the method/platform used.
In addition, we provide validated ER status– and subtype-specific
lncRNA signatures and highlight possible roles of lncRNAs in ER-
and subtype-related pathways. We report that many dysregulated
lncRNAs are related to processes or pathways that play key roles in
breast cancer development, such as immunity and the MAPK, PI3K,
and mTOR pathways. A few of the functions predicted here have been
validated by previous studies, suggesting that our guilt-by-association
approach is effective. For example, PVT1 and MINCR, two lncRNAs
predicted here to play a role in the MYC pathway, were recently found
to controlMYC activity inmammary tumor and in Burkitt’s lymphoma,
respectively (45, 46).
Notably, we show that the lncRNAs that compose our ER-related
signature can be subdivided into three clusters, which predicted to in-
fluence various biological functions previously described in ER signaling.
For instance, the cluster I lncRNAs appear associated with the mTOR
pathway, which drives cell growth and promotes survival. Hyper-
activation of this pathway is involved in the development of ER+ breast
cancer and in resistance to endocrine therapy (47). Further characteri-
zation of the lncRNAs involved in this pathwaymay be of interest in the
search for potential new therapies. Here, we demonstrate an association
of ER-related cluster II lncRNAs,most of which are up-regulated in ER-
negative tumors, with activation of E2F1 signaling. Regulation of E2F1
by ER signaling is reported to mediate resistance to hormone therapyVan Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016(48). Moreover, the E2F1 gene appears more highly expressed in ER
tissues, and high levels of E2F1 transcript correlate with an unfavorable
outcome (49). In cluster III, we highlight lncRNAs that may play roles
related to the immune response. Although the link between ER and the
immune response in breast cancer remains unclear, some studies suggest
that ER plays an immunosuppressive role (50, 51). Furthermore, 9 of the
17 lncRNAs in cluster III are associated with the production of IL-6, a
potential regulatorofnormal and tumor stemcell self-renewal.Abnormally
high IL-6 levels seen in basal-like breast tumors (ER-negative) are asso-
ciated with EMT and with poor clinical outcome (52, 53). Our present
results reveal a potential link between lncRNAs, IL-6 production, and im-
munity in ER-negative tumors.
We have taken a closer look at the identified molecular subtype–
specific lncRNAs, some of which have already been described in breast
cancer. For example, H19, the first identified imprinted lncRNA (54), is
up-regulated in luminal A samples in both our discovery and validation
cohorts. These results agree with in situ hybridization data that show
overexpression of the H19 gene in ER-positive tumors and with the
finding that estradiol transcriptionally regulates H19 (55). Although
H19 and its involvement in breast cancer have been extensively studied,
its function remains unclear because it is reported to both promote and
suppress metastasis (56). The results of our guilt-by-association study
highlight an association of this lncRNA with the TGF-b pathway and
with the EMT, as already described in several studies (57, 58). Our analysis
also linksH19 to epigenetic proteins such as SETD7, KDM1, and EZH1
and provides a new context for further characterization ofH19. In con-
junction with Chen et al. (59), we observed that most of our basal-like–
specific lncRNAs are down-regulated and also identified LINC00993 as
the most down-regulated lncRNA in the basal-like subtype. Our last
example involved HOTAIR; in agreement with a recent study that sug-
gests thatHOTAIRmay be related to theHER2+ subtype (14), we find it
to be themost up-regulated lncRNAof theHER2+ signature. In support
of a link between HER2 and HOTAIR, the latter has recently been re-
ported as anHER2+ regulator in gastric cancer (60).We also predicted a
positive association betweenHOTAIR and the PI3K pathway; this rela-
tionwas recently reported in other cancers (61, 62), but themechanisms
involved are still poorly understood. Therefore, further studies are
needed to better understand HOTAIR/PI3K signaling transduction.
Note that, in addition to linking HOTAIR to the HER2+ and PI3K
pathways, our analysis also links HOTAIR to endocrine therapy
resistance and to other processes, such as histone modification by
EHMT1 (euchromatic histone lysineN-methyltransferase 1) or CREBP
(cAMP response element–binding protein). These links should be
further explored.
Also noteworthy is our observation that subtype-specific lncRNAs
and subtype-specificmRNAs are globally predicted to activate or inhibit
the same pathways. However, some specificities appear. For example,
lncRNAs specific to the basal-like subtype seem particularly involved
in the activation of the EGFR pathway. Amplification of the EGFR gene
is common in basal-like tumors (4). Here, we provide evidence for an
interesting correlation between EGFR gene amplification and lncRNAs
associated with the EGFR pathway. For instance, the gene TPT1-AS1,
which is associated with EGFR pathway activation, is more expressed
in EGFR-amplified tumors, whereas DRAIC, which is associated with
EGFR pathway inhibition, is less expressed in such tumors. This sug-
gests that these EGFR signaling–associated lncRNAs may be regu-
lated by somatic copy number alteration of the EGFR. Overall, we
show that our prediction method provides results in keeping withTable 1. Predicted functions of CYTOR. A selected gene set significantly
associatedwithCYTORby theguilt-by-association analysis (see also table S5).Gene set ScoreEpithelial-mesenchymal transition (HALLMARK_EMT) 2.75Proliferation (BENPORATH_PROLIFERATION) 2.44EGFR signaling (EGFR_UP.V1) 2.33MAPK signaling (MAPK CASCADE.POS) 2.25RAS (MAPK) signaling (RAS.POS) 2.14mTORC signaling (HALLMARK_MTORC_SIGNAL.) 2.12RAF (MAPK) signaling (RAF_UP.V1.POS) 2.12mTOR signaling (MTOR_UP.N4.V1.POS) 1.99Migration (CELL_MIGRATION.POS) 1.929 of 15
R E S EARCH ART I C L Eknown functions of lncRNAs. This lends weight to the hypotheses it
has enabled us to generate regarding new functions of dysregulated
lncRNAs in breast cancer. Confirming these hypotheses may provide
a strong basis for further functional studies.
To test the reliability of the guilt-by-association approach, we
selectedCYTOR for validation. The results of our functional assays con-
firm the predicted involvement of CYTOR in cell proliferation and mi-
gration and its link to the EGFR and mTOR pathways. These findings
support recent studies that show that CYTOR promotes proliferation
(i) in gastric cancer, through the EGFR-dependent pathway (63), and
(ii) in hepatocellular carcinoma, through the mTOR signaling path-
way (64). Moreover, we reveal a drastic reorganization of F-actin
upon CYTOR knockdown. We propose a model wherein CYTOR
ultimately influences F-actin organization by regulating GOLPH3
expression,which in turn regulates cell size (65), and affects themTORC2
complex by controllingmTOR and PRKCA expression. Alternatively,
CYTOR could bind directly to the mTORC2 complex or to modula-
tors of the cytoskeleton. Overall, our data indicate that CYTOR may
be involved in breast cancer development by playing an essential role
in cell proliferation, migration, and morphology. It thus appears as a
potential target for future therapies. Further research is required to
better understand the mechanisms underlying the involvement of
CYTOR in breast cancer.
Besides providing a basis for studying functions of dysregulated
lncRNAs in breast cancer, we also identified and validated a set of 27
lncRNAs predictive of relapse, usingmultivariate Cox analysis.Whereas
most of thesemarkers are novel, some have already been shown in other
studies to have prognostic value. Regarding HOTAIR, which was re-
ported to be a significant predictor of metastasis and death (7), this
lncRNA does not reach statistical relevance in our data set, suggesting
that other lncRNAs identified here could bemore informative with regard
to the probability of relapse. Furthermore, a recent paper demonstrates
that HOTAIR has prognostic value in ER-negative patients only (66).
This may explain why HOTAIR does not emerge as related to relapse
fromour analysis. Globally, these 27 lncRNAsmight have clinical use as
molecular diagnostic markers for identifying patients with low risk of
relapse and who do not need aggressive therapy. We further compared
our list of relapse-associated lncRNAs with recently published survey
of prognostic lncRNAs in breast tumor. Sun et al. (67) identified nine
lncRNAs associated withmetastasis in breast cancer, of which four are
present in the Affymetrix U133 Plus 2.0 array. However, none of them
were significantly associated with relapse in our uni- or multivariate
Cox analysis. Another study identified a set of 45 lncRNAs prognostic
of metastasis in lymph node–negative breast cancer (68); this said, we
found only a small overlap with our results (five and two, respectively,
in common with our uni- and multivariate analysis). This suggests
that additional efforts should be done to robustly identify sets of prog-
nostic lncRNAs.
Overall, our study provides an in-depth analysis of the lncRNA tran-
scriptome in breast cancer and provides numerous new lncRNAmarkers
associated with ER status, tumor subtype, and clinical outcome.We have
inferred functions of these dysregulated lncRNAs, and we demonstrate
for the first time that lncRNAsmight contribute to the dysregulation
of nearly every known breast cancer pathway. These data lay the ground
for future studies that address the biological mechanisms involving
these lncRNAs and their use as diagnostic markers and therapeutic
targets. We have experimentally confirmed the predicted function of
one such dysregulated lncRNA, concluding that our integrative ap-Van Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016proach is effective. These findings should contribute to a better under-
standing of the mechanisms of action of lncRNAs in breast cancer.MATERIALS AND METHODS
Experimental design
The goal of this study was to analyze the transcriptome of breast cancer
in order to identify aberrantly expressed lncRNAs and to infered their
functions.We began by downloading publicly availablemicroarray data
and extracted information on lncRNA expression. We used a specific
method to identify lncRNAs that were dysregulated in small subset of
breast tumors and infer their functions through a guilt-by-association
approach. We have investigated lncRNAs as survival markers. Finally,
wehave characterized the functions of one breast cancer–related lncRNA,
CYTOR, by means of in vitro experiment. The detailed procedure is
described below.
Breast cancer gene expression data and reannotation of the
Affymetrix microarray
To obtain a genome-wide view of lncRNA expression in breast cancer,
we reannotated the entire collection of probe sets of the Affymetrix
Human Genome U133 Plus 2.0 array. We downloaded the microarray
(U133 Plus 2.0Affymetrix) gene expression data sets GSE9195,GSE10780,
GSE10810, GSE12276, GSE19615, GSE20711, andGSE21653 fromGEO
(http://ncbi.nlm.nih.gov/geo/). The raw CEL files were frozen robust
multiarray analysis (fRMA)–normalized in the R environment using
the limma and fRMA libraries to obtain log2-normalized expression
signals for each probe set. We then applied the ComBat algorithm of
the sva librarywith default parameters to adjust the data for batch effects,
using tumor versus normal tissue as covariate. Hybridization probe sets
were locally mapped by sequence alignment (National Center for Bio-
technology InformationBLAST2.2.29+)against a reference transcriptome
in LNCipedia database version 2.1 (69), a database dedicated to
lncRNAs and Ensembl 84 transcriptome. We required that at least 80%
of a probe set should hit a given transcript sequence. For the lncRNAs,
we kept probes that target lncRNAs present in the LNCipedia database.
We then discarded probes that were discordant between LNCipedia
and Ensembl, in terms of transcript biotype. We also excluded probe
sets that targetmultiple genes, except if the targetwas aduplicated lncRNA
(that is, corresponding to a duplicated region of the genome). To identify
these duplicated lncRNAs, we blasted all lncRNA transcripts against
the LNCipedia database, where transcripts were defined as duplicated
if the smallest transcript shared at least 95% of its sequence with the
other. Because these duplicated lncRNAs could not be distinguished
from each other, they were analyzed as arising from a single gene and
the tag “multi” was added to the name of one of them. Alternative
transcripts were considered to be from the same gene. When multiple
probe sets mapped to the same gene (corresponding to an lncRNA or
an mRNA), the one with the highest variance was selected. We com-
puted a full annotation table for the 3053 lncRNAs, comprising their
corresponding names in the Ensembl database (if available), their
genomic location, their category, and the probe sets that matched each
lncRNA (table S2).
Normal breast tissues are composed of a mixture of different cell
types, mainly including epithelial cells and adipocytes, whereas breast
tumors are composed mostly of epithelial cells. Because we focused on
lncRNA genes differentially expressed between normal and cancerous10 of 15
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correlated strongly (Pearson R > 0.6) with adipose markers (70) in
normal breast tissues, suggesting that they might be expressed in adipo-
cytes rather than in epithelial cells.
To assess potential remaining batch effects in the breast cancer data
sets, we performed unsupervised hierarchical clustering of the top 500
most variable genes (coding and noncoding). None of the breast samples
clustered according to the data set they came from, indicating that no
strong batch effect was present.
For the validation steps, the fRMA-normalized data set GSE20685
was downloaded from InSilico DB (www.insilicodb.com). We also
acquired raw data from the TCGA consortium. GSE20685 contains no
normal samples and was therefore not used to validate the dysregulated
lncRNAs in breast cancer.
Clinical data and molecular subtype prediction
The clinical data were downloaded from GEO and were merged (table
S1). In the original studies, the ER and HER2 statuses were determined
by IHC. IntrinsicmRNA-based breast cancer subtypeswere determined
with the 50-gene PAM50 predictor (71).
TCGA RNA-seq analysis
Because the raw RNA-seq data (level 1) from TCGA are challenging to
analyze, we chose to use the TCGA data reprocessed by Rahman et al.
(23) (GSE62944) that allowed to assess the expression of 1241 lncRNAs,
ofwhich 804were present on theAffymetrixmicroarray.We first selected
data from breast tissues and then applied the voom transformation from
the limma package (72, 73) on the transcripts per million expression
values to obtain log2 expression data.
TCGA microarray reannotation
TCGA raw data were processed as previously described (4). Probes
of the TCGA microarray were mapped to the LNCipedia database
using the TCGA annotation file. Briefly, coordinates targeted by
TCGAmicroarray probes were first extracted from the annotation file
“AnotAgilentG4502A_07_3.adf” available on the TCGAWeb site and
converted to hg19 genome build, using liftOver (UCSC). We selected
probes where at least 58 base pairs (bp) of the targeted region over-
lapped, in a strand-specific way, with exons of lncRNA transcripts of
the LNCipedia version 2.1 database. Because the boundaries of exons
are not always clearly defined, we added 5 bp on both sides of each
lncRNA exon. In parallel, probes targeting protein-coding regions were
extracted similarly with Ensembl version 72 and RefSeq version 58.
Finally, probes targeting lncRNAs were only kept for further analysis.
Clustering
For hierarchical clustering, we used the ward.D aggregation method
of the hclust algorithm in R, with the Euclidean distance as the dis-
similarity measure. To maximize the robustness of the clustering to-
ward overfitting, we ran the ConsensusClusterPlus algorithm using
1000 repetitions with subsets obtained by sampling 80% of the samples
[proportion of items (pI), 0.8] and keeping all the features [proportion
of features (pF), 1]. Both inner and final clustering included in this
method were realized with ward.D linkage and Euclidean distance.
Identification of dysregulated lncRNAs
Because breast tumors are highly heterogeneous, classical t tests cannot
identify dysregulated lncRNAs in a small subset of breast tumors.Van Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016Therefore, the method was adapted to identify lncRNAs that were dys-
regulated in at least 10% of the breast tumors (22). This ensured selec-
tion of a reasonable number of dysregulated lncRNAswith a potentially
informative variance related to the heterogeneity of breast cancer. To
find significantly up-regulated genes, we explored the upper tail of the
expression distribution by selecting the 10% of samples (normal or can-
cerous) with the highest expression. We then used a nonparametric
Mann-Whitney test to compare expression levels between the normal
samples and tumor samples. We extended this approach to a growing
proportion of samples (15, 20, 25, 30, 35, 40, and 45%), and all lncRNA
genes additionally found to be differentially expressed were retained. In
parallel, we identified down-regulated lncRNAs by applying the same
methodology to the lower tail of the expression distribution. The 215
lncRNA genes identified as dysregulated had an FDR of <0.05 and a fold
change of >1.5 in at least 10% of the samples.
Prediction of lncRNA functions by the
guilt-by-association approach
This approach is based on establishing correlations between the expres-
sion of lncRNA genes and that of protein-coding genes known to be
involved in particular functions (gene sets). It enabled us to generate
hypotheses regarding the function(s) of a given lncRNA. Publicly avail-
able gene sets were selected from both the KEGG (Kyoto Encyclopedia
of Genes and Genomes) gene set [Molecular Signatures Database
(MsigDB)] and the bdfunc.enrichment.human database of the sRAP
library. Following the guidelines of the GSEA (Gene Set Enrichment
Analysis) software, we grouped gene sets that contain redundant genes
as follows: (i) we computed a between-gene-set distance matrix using
the overlap distance (defined as the number of common genes/number
of genes that compose the smallest gene set); (ii)weperformedhierarchical
clustering on the basis of thismatrix (complete linkage); and (iii)weused a
threshold level of 0.5 to cut the tree and group gene sets that belong to
the same cluster.
We chose to focus only on the potential functions of dysregulated,
ER- and subtype-specific lncRNAs because the guilt-by-association ap-
proach is computation-consuming. First, we randomly divided our
breast tumor expression data into two data sets, one with 411 samples
and one with 412 samples. For each data set, we computed a Pearson
matrix of correlation between each lncRNA and each coding gene to
produce two matrices of 236 lncRNAs × 16,951 mRNAs. In every
matrix, the protein-coding genes were ranked for each lncRNA on
the basis of the correlation coefficient. The GSEA software (parameters,
1000 permutations on gene sets;minimumsize, 15;maximumsize, 500)
was used to calculate a running sum statistic, corresponding to the en-
richment score, on the basis of the ranks of the investigated gene set
members, relative to those of nonmembers. We thus obtained two
matrices containing an enrichment score and a statistical family-wise
error rate (FWER) value for each lncRNA/gene set pair (236 lncRNAs
× 422 gene sets). To obtain high-confidence associations of lncRNAs
with functions, we finally selected gene sets that were statistically (FWER
< 0.05) associated with an lncRNA in both matrices and computed the
mean of their enrichment scores.
To relate clusters of lncRNAs to gene sets, we started by computing,
for each cluster, a metascore of enrichment for a gene set. This meta-
score was defined as the weighted sum of the enrichment scores ob-
tained for the members of the lncRNA cluster, with the weight defined
as −1 if the lncRNA was repressed in the condition of interest and as
1 if otherwise. Then, 10,000 random groups of lncRNAs of the same11 of 15
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lection. For each group, a metascore was generated using the same
weighted sum approach. Finally, the P value of the metascore was
defined as the proportion of randommetascores being at least as high
(low) as the metascore of the positively (negatively) associated cluster.
Signature validation
The different signatures were validated on three cohorts using the
following protocol. First, one should note that for the validation with
the TCGA data, the analysis was restricted to lncRNAs common to
the two platforms. This could lead to a reduction of signature size. In this
case, the size of this “between-platform signature” is specified in themain
text. The data were scaled tomake the two data sets more comparable.
For each signature, ametagenewas then defined for the discovery cohort,
as the first component of a principal components analysis (PCA). A
receiver operating characteristic (ROC) curve was generated from that
metagene, and the threshold that maximizes the Youden index was
selected. Ametagene was then generated from the validation data using
the first component eigenvector from the discovery cohort. For visual-
ization purposes, a ROC curve was generated using this metagene. The
threshold selected for class prediction was the one obtained for the dis-
covery cohort to avoid any bias. Theprediction accuracy of themetagene
was assessed using the balanced error rate (BER)metric. Finally, to eval-
uate the significance of signature performance, we generated 10,000
randomsignatures of the same size as the real between-platformsignature
by randomly sampling lncRNAs. For each random signature, the same
process that was used for the real signature was applied. A P value was
defined as the proportion of random signatures that show a BER lower
than or equal to the real signature, and signatures with a P value lower
than 0.05 were considered significant.
Determination of subtype-specific lncRNA signatures
For each subtype, we first selected lncRNA genes that show significant
differential expression (FDR < 0.05; fold change > 1.5, t test) in one par-
ticular subtype versus the three others. We then filtered out lncRNAs
that were up-regulated (or down-regulated) in more than one subtype
to obtain a list of lncRNAs characteristic of each subtype.
Relapse-free survival analysis
The analysis was computed in R using the “survival” library. The prog-
nostic value of individual lncRNAs was estimated by univariate Cox re-
gression. In parallel, multivariate Cox regression was used to test the
independent prognostic values of lncRNAs, using clinical properties
as covariates. Univariate analysis was used to select covariates that were
prognostic. The proportional hazard assumption was verified with the
“cox.zph” function (threshold, 0.01). For all analyses, P < 0.05 was the
criterion of statistical significance. For visualization purposes, we also
generated Kaplan-Meier curves using the “survfit” function. To define
a high- and low-level group, we assessed all possible thresholds that lead
to groups that represent at least 10% of the data set using the log-rank
test. The threshold that leads to the lowest P value was selected as the
final cutoff for group definition.
A set of 27 lncRNAs associated to relapse-free survival has been val-
idated using a metagene-based approach: a metagene was defined for
the discovery cohort as the first component of a PCA. The metagene
was then generated from the validation data, using the PCA eigenvector
from the discovery cohort. The association of thismetagenewith relapse-
free survival was assessed on the validation cohort using a Cox model.Van Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016The significance of this association can be visualized using forest plot
representation. Because random signatures can be associated to survival
(74), we assessed whether the association of our metagene on the val-
idation cohort is significantly better than metagenes obtained from ran-
domly selected lncRNAs. Therefore, we generated 10,000 random
signatures of the same size as the real relapse-free associated signature
by randomly sampling lncRNAs. For each random signature, the same
process of computing a Cox model from the first eigenvector from the
discovery cohort was applied. Finally, we called “validation P value” the
proportion of random signatures that show a Cox P value lower than or
equal to the real signature. The signature was considered as significant if
the validation P value was lower than 0.05.
Culture of breast cell lines and silencing of target lncRNAs
MDA-MB-231 cells were grown in Dulbecco’s modified Eagle’s medium
(Gibco) supplemented with 10% FBS (Gibco). They were maintained at
37°C in 5% CO2. To silence target lncRNAs, cells were treated with LNA
GapmeRs (Exiqon), according to themanufacturer’s instructions. Briefly,
300,000 cells were transfected in six-well plates with 30 nM LNA Gap-
meRs and 5 ml of Lipofectamine 2000 in 2-ml total volume and were in-
cubated for 24 hours. Staining of F-actin was performed following the
manufacturer’s protocol (http://cytoskeleton.com).
RNA purification and RT-qPCR
RNA purification was performed with the RNeasy kit (Qiagen) ac-
cording to themanufacturer’s instructions. Deoxyribonuclease (DNase)
treatment was performed with a DNA-free DNase kit (Ambion) ac-
cording to the manufacturer’s protocol. qPCRs were performed with
SYBR Green dye (Eurogentec) in LightCycler 480 (Roche). Briefly,
complementary DNA was obtained by reverse transcription of 1 mg
of RNA, with random hexamers (Amersham/Pharmacia Biotech) and
SuperScript II Reverse Transcriptase (Life Technologies Inc.). The
results were normalized against the following housekeeping genes:
SDHA, GAPDH, and ACTIN.
The following LNA gapmer sequences were used: CYTOR LNA, 5′-
TCATAGAGCTTCCTGT-3′.
The following qPCR assay primer sequences were used: CYTOR, 5′-
CTGGATGGTCGCTGCTTTTT-3′ (forward) and 5′-GATCTGAA-
GACAGGCACGGG-3′ (reverse); SMYD3,5′-TTACTGCGAGCAGTCC-
GAGACA-3′ (forward) and 5′-TTGTCCTGGGTTTGGCAACGGA-3′
(reverse); GOLPH3, 5′-CTAGAGGCTTGTGGAATGAGACG-3′ (for-
ward) and 5′-GACCGTTTCTGGAGGCTGAGTT-3′ (reverse); KIF14,
5′-GCACTTTCGGAACAAGCAAACCA-3′ (forward) and 5′-ATGT-
TGCTGGCAGCGGGACTAA-3′ (reverse); mTOR, 5′-AGCATCG-
GATGCTTAGGAGTGG-3′ (forward) and 5′-CAGCCAGTCATCTTTG-
GAGACC-3′ (reverse); PRKCA, 5′-GCCTATGGCGTCCTGTTGTATG-
3′ (forward) and 5′-GAAACAGCCTCCTTGGACAAGG-3′ (reverse).
Cell proliferation/migration
To evaluate breast cancer cell proliferation, MDA-MB-231 cells
(10,000 per well) transfected with LNA gapmers were seeded into
the xCELLigence E-Plate 16 (Roche) 24 hours after transfection,
according to themanufacturer’s instructions. In this system, the elec-
trical impedance is used to derive a cell index, which gives a real-time
representation of cell growth when continuously monitored. Mea-
surements were automatically collected by the RTCA Dual Plate an-
alyzer every 30 min for up to 3 days. The data were analyzed with the
RTCA software.12 of 15
R E S EARCH ART I C L ETo examine breast cancer cell migration, MDA-MB-231 cells trans-
fectedwith LNA gapmerswere seeded into the xCELLigence CIM-Plate
16 (Roche) 24 hours after transfection. Briefly, a 165-ml volume of fresh
medium containing 10% FBS (chemoattractant) or serum-freemedium
(control) was added to the lower chambers of the CIM-Plate 16. The
upper chambers were filled with serum-free medium (30 ml per well),
and the plate was incubated in 5% CO2 for 1 hour at 37°C. Cells
(20,000 per well) were then added to each well of the upper chamber,
and cell migration was assessed at 30-min intervals for 18 hours at
37°C in 5% CO2. Upon migration, cells adhere to the surface of the
filter electrode and increase the impedance.
Cell cycle analysis by flow cytometry
The distribution of cells through the various phases of the cell cycle was
determined by measuring the DNA content with BD BrdU Flow kits
(catalog no. 552598) according to the manufacturer’s instructions.
Briefly, cells were incubated with 10 mM BrdU for 2 hours. They were
then fixed with paraformaldehyde, permeabilized with saponin, and
treated with DNase to expose the BrdU epitope. BrdU was stained with
fluorescent anti-BrdU antibodies. The total DNA level was assessed by
staining with 7-AAD. Data were analyzed with the Kaluza Analysis
Software (Beckman Coulter).
Illumina Expression HT12 arrays
Total RNA (200 ng) was amplified with the Illumina TotalPrep RNA
Amplification Kit (Ambion) and then hybridized with the array
according to theWhole-GenomeGene ExpressionDirect Hybridization
Assay (Illumina). Chipswere scannedwith theHiScanReader (Illumina).
The raw data were normalized using the quantile normalization
method from the lumi package (75), and batch effect was corrected with
the ComBat algorithm of the sva library with default parameters, using
the CYTOR status (LNA-silenced versus control) as covariate. Then, to
identify probes that are differentially expressed, a t test was applied,
and the P values obtained were corrected for multitesting using the
Benjamini-Hochberg method. The probes that simultaneously show
an FDR of <0.05 and an absolute fold change between themedian of each
group higher than 1.5 were reported as differentially expressed if the
median expression value in each group was significantly higher than the
background level (detection P value < 0.05). The raw data have been up-
loaded inGEOdatabase and are accessible under accessionno.GSE77491.
Statistical analysis
Data values were expressed as means ± SD of at least two independent
experiments and evaluated using Student’s t test for unpaired samples,
or otherwise specified. Mean differences were considered significant
when P < 0.05, or otherwise specified.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/2/9/e1600220/DC1
fig. S1. Dysregulated lncRNAs in breast tumors.
fig. S2. Validation of the ER-related lncRNA signature in three data sets.
fig. S3. Validation of the subtype-specific lncRNA signature in three data sets.
fig. S4. Validation of the set of 27 lncRNAs predictive of relapse and dysregulated in breast cancer.
fig. S5. Methylation of the CYTOR gene in relation to its expression.
fig. S6. Impact of CYTOR depletion on cell cycle and gene expression.
table S1. Clinical annotation of the 823 primary tumors and the 172 normal tissue samples
from the discovery cohort, including age, size, lymph node status, ER status, HER2 status,
grade, PAM50-associated subtype, and relapse information.Van Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 2016table S2. Reannotation of the Affymetrix Human Genome U133 Plus 2.0 array.
table S3. Description of the 215 dysregulated lncRNAs in breast cancer.
table S4. Contingency table of the lncRNA-related clusters that correlate with ER status.
table S5. Significant enrichment scores from the guilt-by-association analysis.
table S6. Contingency table of the lncRNA-related clusters that correlate with the known
molecular subtypes.
table S7. lncRNAs signatures of the known molecular subtypes of breast cancer.
table S8. Survival analysis: Univariate results.
table S9. Survival analysis: Multivariate results.REFERENCES AND NOTES
1. J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin,
D. Forman, F. Bray, GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11 (International Agency for Research on Cancer, Lyon, 2012).
2. C. M. Perou, T. Sørlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack,
D. T. Ross, H. Johnsen, L. A. Akslen, Ø. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu,
P. E. Lønning, A.-L. Børresen-Dale, P. O. Brown, D. Botstein, Molecular portraits of human
breast tumours. Nature 406, 747–752 (2000).
3. E. Senkus, S. Kyriakides, S. Ohno, F. Penault-Llorca, P. Poortmans, E. Rutgers, S. Zackrisson,
F. Cardoso, Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treat-
ment and follow-up. Ann. Oncol. 26 (Suppl. 5), v8–v30 (2015).
4. The. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast
tumours. Nature 490, 61–70 (2012).
5. J. S. Reis-Filho, L. Pusztai, Gene expression profiling in breast cancer: Classification, prognostica-
tion, and prediction. Lancet 378, 1812–1823 (2011).
6. L. Pusztai, R. Rouzier, W. F. Symmans, CCR 20th anniversary commentary: Divide and conquer—
Breast cancer subtypes and response to therapy. Clin. Cancer Res. 21, 3575–3577 (2015).
7. R. A. Gupta, N. Shah, K. C. Wang, J. Kim, H. M. Horlings, D. J. Wong, M.-C. Tsai, T. Hung,
P. Argani, J. L. Rinn, Y. Wang, P. Brzoska, B. Kong, R. Li, R. B. West, M. J. van de Vijver,
S. Sukumar, H. Y. Chang, Long non-coding RNA HOTAIR reprograms chromatin state to
promote cancer metastasis. Nature 464, 1071–1076 (2010).
8. J. M. Silva, N. J. Boczek, M. W. Berres, X. Ma, D. I. Smith, LSINCT5 is over expressed in breast
and ovarian cancer and affects cellular proliferation. RNA Biol. 8, 496–505 (2011).
9. T. Derrien, R. Johnson, G. Bussotti, A. Tanzer, S. Djebali, H. Tilgner, G. Guernec, D. Martin,
A. Merkel, D. G. Knowles, J. Lagarde, L. Veeravalli, X. Ruan, Y. Ruan, T. Lassmann, P. Carninci,
J. B. Brown, L. Lipovich, J. M. Gonzalez, M. Thomas, C. A. Davis, R. Shiekhattar, T. R. Gingeras,
T. J. Hubbard, C. Notredame, J. Harrow, R. Guigó, The GENCODE v7 catalog of human long
noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res.
22, 1775–1789 (2012).
10. T. Gutschner, S. Diederichs, The hallmarks of cancer: A long non-coding RNA point of view.
RNA Biol. 9, 703–719 (2012).
11. M. Esteller, Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861–874 (2011).
12. M. Huarte, M. Guttman, D. Feldser, M. Garber, M. J. Koziol, D. Kenzelmann-Broz, A. M. Khalil,
O. Zuk, I. Amit, M. Rabani, L. D. Attardi, A. Regev, E. S. Lander, T. Jacks, J. L. Rinn, A large
intergenic noncoding RNA induced by p53 mediates global gene repression in the p53
response. Cell 142, 409–419 (2010).
13. S. W. Cheetham, F. Gruhl, J. S. Mattick, M. E. Dinger, Long noncoding RNAs and the genetics of
cancer. Br. J. Cancer 108, 2419–2425 (2013).
14. X. Su, G. G. Malouf, Y. Chen, J. Zhang, H. Yao, V. Valero, J. N. Weinstein, J.-P. Spano,
F. Meric-Bernstam, D. Khayat, F. J. Esteva, Comprehensive analysis of long non-coding
RNAs in human breast cancer clinical subtypes. Oncotarget 5, 9864–9876 (2014).
15. W. Zhao, J. Luo, S. Jiao, Comprehensive characterization of cancer subtype associated long
non-coding RNAs and their clinical implications. Sci. Rep. 4, 6591 (2014).
16. L. M. McIntyre, K. K. Lopiano, A. M. Morse, V. Amin, A. L. Oberg, L. J. Young, S. V. Nuzhdin,
RNA-seq: Technical variability and sampling. BMC Genomics 12, 293 (2011).
17. N. Raghavachari, J. Barb, Y. Yang, P. Liu, K. Woodhouse, D. Levy, C. J. O’Donnell,
P. J. Munson, G. J. Kato, A systematic comparison and evaluation of high density exon
arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of
sickle cell disease. BMC Med. Genomics 5, 28 (2012).
18. L. Jiang, F. Schlesinger, C. A. Davis, Y. Zhang, R. Li, M. Salit, T. R. Gingeras, B. Oliver, Synthetic
spike-in standards for RNA-seq experiments. Genome Res. 21, 1543–1551 (2011).
19. R. Edgar, M. Domrachev, A. E. Lash, Gene Expression Omnibus: NCBI gene expression and
hybridization array data repository. Nucleic Acids Res. 30, 207–210 (2002).
20. S. Monti, P. Tamayo, J. Mesirov, T. Golub, Consensus clustering: A resampling-based
method for class discovery and visualization of gene expression microarray data. Mach.
Learn. 52, 91–118 (2003).
21. M. D. Wilkerson, D. N. Hayes, ConsensusClusterPlus: A class discovery tool with confidence
assessments and item tracking. Bioinformatics 26, 1572–1573 (2010).13 of 15
R E S EARCH ART I C L E22. L. Yao, H. Shen, P. W. Laird, P. J. Farnham, B. P. Berman, Inferring regulatory element landscapes
and transcription factor networks from cancer methylomes. Genome Biol. 16, 105 (2015).
23. M. Rahman, L. K. Jackson, W. E. Johnson, D. Y. Li, A. H. Bild, S. R. Piccolo, Alternative pre-
processing of RNA-sequencing data in The Cancer Genome Atlas leads to improved analysis
results. Bioinformatics 31, 3666–3672 (2015).
24. D. Chakravarty, A. Sboner, S. S. Nair, E. Giannopoulou, R. Li, S. Hennig, J. M. Mosquera,
J. Pauwels, K. Park, M. Kossai, T. Y. MacDonald, J. Fontugne, N. Erho, I. A. Vergara,
M. Ghadessi, E. Davicioni, R. B. Jenkins, N. Palanisamy, Z. Chen, S. Nakagawa, T. Hirose,
N. H. Bander, H. Beltran, A. H. Fox, O. Elemento, M. A. Rubin, The oestrogen receptor
a-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat. Commun. 5,
5383 (2014).
25. H. Hansji, E. Y. Leung, B. C. Baguley, G. J. Finlay, M. E. Askarian-Amiri, Keeping abreast with
long non-coding RNAs in mammary gland development and breast cancer. Front. Genet. 5,
379 (2014).
26. N. C. Turner, J. S. Reis-Filho, A. M. Russell, R. J. Springall, K. Ryder, D. Steele, K. Savage,
C. E. Gillett, F. C. Schmitt, A. Ashworth, A. N. Tutt, BRCA1 dysfunction in sporadic basal-like
breast cancer. Oncogene 26, 2126–2132 (2007).
27. J. L. Rinn, H. Y. Chang, Genome regulation by long noncoding RNAs. Annu. Rev. Biochem.
81, 145–166 (2012).
28. M. F. Montenegro, M. d. M. Collado-González, M. P. Fernández-Pérez, M. B. Hammouda,
L. Tolordava, M. Gamkrelidze, J. N. Rodríguez-López, Promoting E2F1-mediated apoptosis
in oestrogen receptor-a-negative breast cancer cells. BMC Cancer 14, 539 (2014).
29. X. Jiang, D. J. Shapiro, The immune system and inflammation in breast cancer. Mol. Cell.
Endocrinol. 382, 673–682 (2014).
30. C. Sweeney, P. S. Bernard, R. E. Factor, M. L. Kwan, L. A. Habel, C. P. Quesenberry,
K. Shakespear, E. K. Weltzien, I. J. Stijleman, C. A. Davis, M. T. W. Ebbert, A. Castillo,
L. H. Kushi, B. J. Caan, Intrinsic subtypes from PAM50 gene expression assay in a population-
based breast cancer cohort: Differences by age, race, and tumor characteristics. Cancer
Epidemiol. Biomarkers Prev. 23, 714–724 (2014).
31. L. Zheng, J. Q. Ren, H. Li, Z. L. Kong, H. G. Zhu, Downregulation of wild-type p53 protein by
HER-2/neu mediated PI3K pathway activation in human breast cancer cells: Its effect on
cell proliferation and implication for therapy. Cell Res. 14, 497–506 (2004).
32. S. Grivennikov, M. Karin, Autocrine IL-6 signaling: A key event in tumorigenesis? Cancer Cell
13, 7–9 (2008).
33. Z. Du, T. Fei, R. G. W. Verhaak, Z. Su, Y. Zhang, M. Brown, Y. Chen, X. S. Liu, Integrative
genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat.
Struct. Mol. Biol. 20, 908–913 (2013).
34. M. W. Wright, A short guide to long non-coding RNA gene nomenclature. Hum. Genomics
8, 7 (2014).
35. Q. Pang, J. Ge, Y. Shao, W. Sun, H. Song, T. Xia, B. Xiao, J. Guo, Increased expression of long
intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. Tumour
Biol. 35, 5441–5447 (2014).
36. M. K. Iyer, Y. S. Niknafs, R. Malik, U. Singhal, A. Sahu, Y. Hosono, T. R. Barrette, J. R. Prensner,
J. R. Evans, S. Zhao, A. Poliakov, X. Cao, S. M. Dhanasekaran, Y.-M. Wu, D. R. Robinson,
D. G. Beer, F. Y. Feng, H. K. Iyer, A. M. Chinnaiyan, The landscape of long noncoding RNAs
in the human transcriptome. Nat. Genet. 47, 199–208 (2015).
37. A. C. Marques, J. Hughes, B. Graham, M. S. Kowalczyk, D. R. Higgs, C. P. Ponting, Chromatin
signatures at transcriptional start sites separate two equally populated yet distinct classes
of intergenic long noncoding RNAs. Genome Biol. 14, R131 (2013).
38. S. M. Singel, C. Cornelius, E. Zaganjor, K. Batten, V. R. Sarode, D. L. Buckley, Y. Peng,
G. B. John, H. C. Li, N. Sadeghi, W. E. Wright, L. Lum, T. W. Corson, J. W. Shay, KIF14 promotes
AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer.
Neoplasia 16, 247–256.e2 (2014).
39. Z. Zeng, H. Lin, X. Zhao, G. Liu, X. Wang, R. Xu, K. Chen, J. Li, L. Song, Overexpression of
GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the
FOXO1 transcription factor. Clin. Cancer Res. 18, 4059–4069 (2012).
40. R. Keil, J. Schulz, M. Hatzfeld, p0071/PKP4, a multifunctional protein coordinating cell adhesion
with cytoskeletal organization. Biol. Chem. 394, 1005–1017 (2013).
41. T. Wakatsuki, R. B. Wysolmerski, E. L. Elson, Mechanics of cell spreading: Role of myosin II.
J. Cell Sci. 116, 1617–1625 (2003).
42. D. D. Sarbassov, S. M. Ali, D.-H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage,
P. Tempst, D. M. Sabatini, Rictor, a novel binding partner of mTOR, defines a rapamycin-
insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol.
14, 1296–1302 (2004).
43. P. Jonsson, C. Coarfa, F. Mesmar, T. Raz, K. Rajapakshe, J. F. Thompson, P. H. Gunaratne,
C. Williams, Single-molecule sequencing reveals estrogen-regulated clinically relevant
lncRNAs in breast cancer. Mol. Endocrinol. 29, 1634–1645 (2015).
44. V. Miano, G. Ferrero, S. Reineri, L. Caizzi, L. Annaratone, L. Ricci, S. Cutrupi, I. Castellano,
F. Cordero, M. De Bortoli, Luminal long non-coding RNAs regulated by estrogen receptor a
in a ligand-independent manner show functional roles in breast cancer. Oncotarget 7,
3201–3216 (2016).Van Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 201645. Y.-Y. Tseng, B. S. Moriarity, W. Gong, R. Akiyama, A. Tiwari, H. Kawakami, P. Ronning,
B. Reuland, K. Guenther, T. C. Beadnell, J. Essig, G. M. Otto, M. G. O ’Sullivan,
D. A. Largaespada, K. L. Schwertfeger, Y. Marahrens, Y. Kawakami, A. Bagchi,
PVT1 dependence in cancer with MYC copy-number increase. Nature 512, 82–86
(2014).
46. G. Doose, A. Haake, S. H. Bernhart, C. López, S. Duggimpudi, F. Wojciech, A. K. Bergmann,
A. Borkhardt, B. Burkhardt, A. Claviez, L. Dimitrova, S. Haas, J. I. Hoell, M. Hummel, D. Karsch,
W. Klapper, K. Kleo, H. Kretzmer, M. Kreuz, R. Küppers, C. Lawerenz, D. Lenze, M. Loeffler,
L. Mantovani-Löffler, P. Möller, G. Ott, J. Richter, M. Rohde, P. Rosenstiel, A. Rosenwald,
M. Schilhabel, M. Schneider, I. Scholz, S. Stilgenbauer, H. G. Stunnenberg, M. Szczepanowski,
L. Trümper, M. A. Weniger; ICGC MMML-Seq Consortium, S. Hoffmann, R. Siebert, I. Iaccarino,
MINCR is a MYC-induced lncRNA able to modulate MYC’s transcriptional network in Burkitt
lymphoma cells. Proc. Natl. Acad. Sci. U.S.A. 112, E5261–E5270 (2015).
47. E. M. Ciruelos Gil, Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive
breast cancer. Cancer Treat. Rev. 40, 862–871 (2014).
48. M. C. Louie, A. McClellan, C. Siewit, L. Kawabata, Estrogen receptor regulates E2F1 expression
to mediate tamoxifen resistance. Mol. Cancer Res. 8, 343–352 (2010).
49. V. Vuaroqueaux, P. Urban, M. Labuhn, M. Delorenzi, P. Wirapati, C. C. Benz, R. Flury,
H. Dieterich, F. Spyratos, U. Eppenberger, S. Eppenberger-Castori, Low E2F1 transcript
levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res.
9, R33 (2007).
50. E. M. Curran, B. M. Judy, N. A. Duru, H.-Q. Wang, L. A. Vergara, D. B. Lubahn, D. M. Estes,
Estrogenic regulation of host immunity against an estrogen receptor–negative human
breast cancer. Clin. Cancer Res. 12, 5641–5647 (2006).
51. A. A. Mostafa, D. Codner, K. Hirasawa, Y. Komatsu, M. N. Young, V. Steimle, S. Drover, Activation
of ERa signaling differentially modulates IFN-g induced HLA-class II expression in breast cancer
cells. PLOS One 9, e87377 (2014).
52. N. J. Sullivan, A. K. Sasser, A. E. Axel, F. Vesuna, V. Raman, N. Ramirez, T. M. Oberyszyn,
B. M. Hall, Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human
breast cancer cells. Oncogene 28, 2940–2947 (2009).
53. Z. T. Schafer, J. S. Brugge, IL-6 involvement in epithelial cancers. J. Clin. Invest. 117,
3660–3663 (2007).
54. N. Berteaux, N. Aptel, G. Cathala, C. Genton, J. Coll, A. Daccache, N. Spruyt, H. Hondermarck,
T. Dugimont, J.-J. Curgy, T. Forné, E. Adriaenssens, A novel H19 antisense RNA overexpressed
in breast cancer contributes to paternal IGF2 expression. Mol. Cell. Biol. 28, 6731–6745
(2008).
55. E. Adriaenssens, L. Dumont, S. Lottin, D. Bolle, A. Leprêtre, A. Delobelle, F. Bouali,
T. Dugimont, J. Coll, J.-J. Curgy, H19 overexpression in breast adenocarcinoma stromal
cells is associated with tumor values and steroid receptor status but independent of
p53 and Ki-67 expression. Am. J. Pathol. 153, 1597–1607 (1998).
56. L. Zhang, F. Yang, J.-h. Yuan, S.-x. Yuan, W.-p. Zhou, X.-s. Huo, D. Xu, H.-s. Bi, F. Wang,
S.-h. Sun, Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis
suppression in hepatocellular carcinoma. Carcinogenesis 34, 577–586 (2013).
57. R. Bergström, K. Savary, A. Morén, S. Guibert, C.-H. Heldin, R. Ohlsson, A. Moustakas,
Transforming growth factor b promotes complexes between Smad proteins and the
CCCTC-binding factor on the H19 imprinting control region chromatin. J. Biol. Chem.
285, 19727–19737 (2010).
58. I. J. Matouk, E. Raveh, R. Abu-lail, S. Mezan, M. Gilon, E. Gershtain, T. Birman, J. Gallula,
T. Schneider, M. Barkali, C. Richler, Y. Fellig, V. Sorin, A. Hubert, A. Hochberg, A. Czerniak,
Oncofetal H19 RNA promotes tumor metastasis. Biochim. Biophys. Acta 1843, 1414–1426
(2014).
59. C. Chen, Z. Li, Y. Yang, T. Xiang, W. Song, S. Liu, Microarray expression profiling of dysregulated
long non-coding RNAs in triple-negative breast cancer. Cancer Biol. Ther. 16, 856–865
(2015).
60. X.-H. Liu, M. Sun, F.-q. Nie, Y.-b. Ge, E.-b. Zhang, D.-d. Yin, R. Kong, R. Xia, K.-h. Lu, J.-h. Li,
W. De, K.-m. Wang, Z.-x. Wang, Lnc RNA HOTAIR functions as a competing endogenous
RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol. Cancer
13, 92 (2014).
61. G. Yang, S. Zhang, F. Gao, Z. Liu, M. Lu, S. Peng, T. Zhang, F. Zhang, Osteopontin enhances
the expression of HOTAIR in cancer cells via IRF1. Biochim. Biophys. Acta 1839, 837–848
(2014).
62. Z. Hui, M. Xianglin, Association of HOTAIR expression with PI3K/Akt pathway activation in
adenocarcinoma of esophagogastric junction. Open Med. 11, 36–40 (2016).
63. J. Zhou, X. Zhi, L. Wang, W. Wang, Z. Li, J. Tang, J. Wang, Q. Zhang, Z. Xu, Linc00152 pro-
motes proliferation in gastric cancer through the EGFR-dependent pathway. J. Exp. Clin.
Cancer Res. 34, 135 (2015).
64. J. Ji, J. Tang, L. Deng, Y. Xie, R. Jiang, G. Li, B. Sun, LINC00152 promotes proliferation in
hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. Oncotarget
6, 42813–42824 (2015).
65. K. L. Scott, O. Kabbarah, M.-C. Liang, E. Ivanova, V. Anagnostou, J. Wu, S. Dhakal, M. Wu,
S. Chen, T. Feinberg, J. Huang, A. Saci, H. R. Widlund, D. E. Fisher, Y. Xiao, D. L. Rimm,14 of 15
R E S EARCH ART I C L EA. Protopopov, K.-K. Wong, L. Chin, GOLPH3 modulates mTOR signalling and rapamycin
sensitivity in cancer. Nature 459, 1085–1090 (2009).
66. Y. Gökmen-Polar, I. T. Vladislav, Y. Neelamraju, S. C. Janga, S. Badve, Prognostic impact
of HOTAIR expression is restricted to ER-negative breast cancers. Sci. Rep. 5, 8765
(2015).
67. J. Sun, X. Chen, Z. Wang, M. Guo, H. Shi, X. Wang, L. Cheng, M. Zhou, A potential prognostic
long non-coding RNA signature to predict metastasis-free survival of breast cancer pa-
tients. Sci. Rep. 5, 16553 (2015).
68. K. P. Sørensen, M. Thomassen, Q. Tan, M. Bak, S. Cold, M. Burton, M. J. Larsen, T. A. Kruse,
Long non-coding RNA expression profiles predict metastasis in lymph node-negative
breast cancer independently of traditional prognostic markers. Breast Cancer Res. 17, 55 (2015).
69. P.-J. Volders, K. Helsens, X. Wang, B. Menten, L. Martens, K. Gevaert, J. Vandesompele,
P. Mestdagh, LNCipedia: A database for annotated human lncRNA transcript sequences
and structures. Nucleic Acids Res. 41, D246–D251 (2013).
70. P. Stępniak, M. Maycock, K. Wojdan, M. Markowska, S. Perun, A. Srivastava, L. S. Wyrwicz,
K. Świrski, Microarray Inspector: Tissue cross contamination detection tool for microarray
data. Acta Biochim. Pol. 60, 647–655 (2013).
71. J. S. Parker, M. Mullins, M. C. U. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron,
X. He, Z. Hu, J. F. Quackenbush, I. J. Stijleman, J. Palazzo, J. S. Marron, A. B. Nobel, E. Mardis,
T. O. Nielsen, M. J. Ellis, C. M. Perou, P. S. Bernard, Supervised risk predictor of breast cancer
based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
72. C. W. Law, Y. Chen, W. Shi, G. K. Smyth, voom: Precision weights unlock linear model anal-
ysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
73. M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, G. K. Smyth, limma powers dif-
ferential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res.
43, e47 (2015).
74. D. Venet, J. E. Dumont, V. Detours, Most random gene expression signatures are signifi-
cantly associated with breast cancer outcome. PLOS Comput. Biol. 7, e1002240 (2011).Van Grembergen et al. Sci. Adv. 2016; 2 : e1600220 2 September 201675. P. Du, W. A. Kibbe, S. M. Lin, lumi: A pipeline for processing Illumina microarray. Bioinformatics
24, 1547–1548 (2008).
Acknowledgments: We thank J. Vandesompele, P. Mestdag, H. Duvillier, and S. Garaud for
their helpful advice. Funding: O.V.G. was supported by the Télévie. M.B. was supported by
the Télévie. M.D. was supported by the Walloon Region (WB Health grant, CanDx). E.J.d.B.
was supported by the Belgian F.R.I.A. This work was funded by grants from the Fonds de la
Recherche Scientifique and Télévie, as well as by grants from the IUAP P7/03 program, the
Action de Recherche Concerté (AUWB-2010-2015 ULB-No 7), the Belgian “Foundation
against Cancer,” the WB Health program, and the Fonds Gaston Ithier. Author contribu-
tions: O.V.G. and F.F. designed the experiments and interpreted the data. O.V.G., M.B., E.J.d.B., C.O.,
S.B., and M.D. performed the bioinformatics analysis. O.V.G., E.C., and P.P. performed the
qPCR and proliferation/migration experiments. M.G., G.B., and C.S. provided technical
support and advices. F.F. directed the study, and O.V.G. and F.F. wrote the article. Competing
interests: G.B., C.S., and F.F. are Université Libre de Bruxelles professors. The other authors
declare that they have no competing interests. Data and materials availability: All data
needed to evaluate the conclusions in the paper are present in the paper and/or the Sup-
plementary Materials. Additional data related to this paper may be requested from the
authors.
Submitted 4 February 2016
Accepted 5 August 2016
Published 2 September 2016
10.1126/sciadv.1600220
Citation: O. Van Grembergen, M. Bizet, E. J. de Bony, E. Calonne, P. Putmans, S. Brohée,
C. Olsen, M. Guo, G. Bontempi, C. Sotiriou, M. Defrance, F. Fuks, Portraying breast cancers
with long noncoding RNAs. Sci. Adv. 2, e1600220 (2016).15 of 15
